{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:42:00Z","timestamp":1790707320025,"version":"4.1.0"},"reference-count":39,"publisher":"Wiley","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>To evaluate the clinical efficacy and cost\u2010effectiveness of golidocitinib, a novel JAK1 inhibitor, versus chidamide, a histone deacetylase inhibitor, for relapsed\/refractory peripheral T\u2010cell lymphoma (r\/rPTCL) in the Chinese healthcare system, providing preliminary comparative evidence for these targeted therapies in the absence of head \u2010 to \u2010 head trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A matching\u2010adjusted indirect comparison (MAIC) harmonized baseline characteristics between golidocitinib (manufacturer\u2010provided JACKPOT8 trial individual patient data) and chidamide (aggregated trial data). A partitioned survival model adopted the Chinese healthcare system perspective, with drug costs modelled using time\u2010to\u2010discontinuation to reflect persistence. Outcomes included lifetime costs, quality\u2010adjusted life years (QALYs) and incremental cost\u2010effectiveness ratios (ICERs) against China's willingness\u2010to\u2010pay (WTP) threshold ($13455.00\/QALY). Robustness was tested via scenario analyses (10\u2010year horizon, progression\u2010free survival\u2010based costing), deterministic sensitivity analysis and probabilistic Monte Carlo simulations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Post\u2010MAIC, golidocitinib significantly improved median progression\u2010free survival (5.6 <jats:italic>vs<\/jats:italic> 2.1\u2009months, hazard ratio [HR]\u2009=\u20090.502, 95% confidence interval [CI] 0.348\u20100.724, <jats:italic>P<\/jats:italic>\u2009&lt;\u2009.001) but not overall survival (median NR <jats:italic>vs<\/jats:italic> 21.4\u2009months, HR\u2009=\u20090.846, 95% CI 0.549\u20101.302, <jats:italic>P<\/jats:italic>\u2009=\u2009.428) <jats:italic>vs<\/jats:italic> chidamide. Base\u2010case analysis showed golidocitinib incurred higher costs ($46702.13 <jats:italic>vs<\/jats:italic> $37219.44) but gained 1.35 QALYs, yielding an ICER of $7006.15\/QALY (95% CI $4140.94\u201010355.49), below China's threshold. All sensitivity analyses supported base\u2010case conclusions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Golidocitinib demonstrates potential cost\u2010effectiveness versus chidamide for r\/rPTCL in China. While definitive conclusions await head\u2010to\u2010head trials, these MAIC\u2010adjusted results provide preliminary evidence for resource allocation decisions.<\/jats:p><\/jats:sec>","DOI":"10.1002\/bcp.70269","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T05:14:30Z","timestamp":1757740470000},"source":"Crossref","is-referenced-by-count":1,"title":["Golidocitinib and chidamide for refractory or relapsed peripheral T\u2010cell lymphoma: A preliminary cost\u2010effectiveness analysis in China"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8439-8778","authenticated-orcid":false,"given":"Tianyu","family":"Jing","sequence":"first","affiliation":[{"name":"School of International Pharmaceutical Business China Pharmaceutical University  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Du","sequence":"additional","affiliation":[{"name":"School of International Pharmaceutical Business China Pharmaceutical University  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Tan","sequence":"additional","affiliation":[{"name":"School of International Pharmaceutical Business China Pharmaceutical University  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingkai","family":"Zha","sequence":"additional","affiliation":[{"name":"School of Public Health Fudan University  Shanghai China"},{"name":"National Health Commission Key Laboratory of Health Technology Assessment Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kefan","family":"Shi","sequence":"additional","affiliation":[{"name":"School of International Pharmaceutical Business China Pharmaceutical University  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6925-0636","authenticated-orcid":false,"given":"Wei","family":"Xu","sequence":"additional","affiliation":[{"name":"School of International Pharmaceutical Business China Pharmaceutical University  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010022\u201001620\u20102"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164\u2010020\u201000188\u2010w"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2017.05.005"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.16.4558"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912\u2010022\u201001310\u20103"},{"key":"e_1_2_11_7_1","unstructured":"Ferlay J ErvikM Lam F et al.Global Cancer Observatory: Globocan 2022. Version 1.1 ed. Accessed December 20 2024.https:\/\/gco.iarc.who.int\/today"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.186577"},{"key":"e_1_2_11_9_1","unstructured":"National Comprehensive Cancer Network.Clinical Practice Guidelines in Oncology: T\u2010Cell Lymphomas. Version 1.2025 ed. Accessed January 02 2025.https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/t-cell.pdf"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.08.013"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.ade8520"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.adf1329"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(23)00589\u20102"},{"key":"e_1_2_11_14_1","volume-title":"Guidelines of Chinese Society of clinical oncology (CSCO): lymphoid malignancies","author":"Chinese Society of Clinical Oncology Guidelines Working Committee","year":"2024"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70128"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv237"},{"key":"e_1_2_11_17_1","unstructured":"David MP Ades A. E. DiasS PalmerS AbramsKR WeltonN.NICE DSU technical support document 18: methods for population\u2010adjusted indirect comparisons in submission to NICE. Accessed December 20 2024.https:\/\/www.sheffield.ac.uk\/media\/34216\/download?attachment?attachment"},{"key":"e_1_2_11_18_1","unstructured":"Beth W Eleftherios S Stephen P Nick L Marta S.NICE DSU technical support document 19: partitioned survival analysis for decision modelling in health care: a critical review. Accessed December 20 2024.https:\/\/www.sheffield.ac.uk\/media\/34205\/download?attachment"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2023.2254640"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462320002081"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.03.005"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.19450\/j.cnki.jcrh.2022.05.006"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.10.008"},{"issue":"09","key":"e_1_2_11_24_1","first-page":"1096","article-title":"Introduction and application example of unanchored matching\u2010adjusted indirect comparison method","volume":"23","author":"Liu Y","year":"2023","journal-title":"Chin J Evid Based Med"},{"issue":"01","key":"e_1_2_11_25_1","first-page":"105","article-title":"Matching\u2010adjusted indirect comparison for survival data analysis: implementation in R language","volume":"24","author":"Hu H","year":"2024","journal-title":"Chin J Evid Based Med"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874\u2010021\u201001308\u20108"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v070.i08"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471\u20102288\u201012\u20109"},{"key":"e_1_2_11_29_1","unstructured":"Chinese Center for Drug Evaluation.Package insert of chidamide tablets. Accessed December 20 2024.https:\/\/www.cde.org.cn\/main\/xxgk\/postmarketpage?acceptidCODE=c0d18cee375aeaf451c1de037d1ae1e5"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524\u20104733.2005.00037.x"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.970542"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325\u2010023\u201002444\u2010x"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885\u2010020\u201007629\u2010z"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.13683\/j.wph.2022.06.015"},{"key":"e_1_2_11_35_1","unstructured":"Yaozhiwang.Market Inform2024 Dec 20.https:\/\/data.yaozh.com\/"},{"issue":"03","key":"e_1_2_11_36_1","first-page":"55","article-title":"Home vs nursing home: end\u2010of\u2010life care expenditure and quality of dying in elderly populations","author":"Gong X","year":"2020","journal-title":"Soc Secur Stud"},{"key":"e_1_2_11_37_1","volume-title":"China guidelines for pharmacoeconomic evaluations","author":"Liu G","year":"2020"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/hec.1612"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273\u2010015\u20100254\u20102"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16181"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70269","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T05:14:34Z","timestamp":1757740474000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":39,"alternative-id":["10.1002\/bcp.70269"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70269","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,12]]},"article-number":"bcp.70269"}}